Development and Validation of HPLC Method for Simultaneous Estimation of Cilnidipine and Valsartan in Bulk and Tablet Dosage Form
キーワード:
Cilnidipine、 Valsartan、 simultaneous estimation、 validation、 RP-HPLC要旨
A simple, sensitive, accurate and precise reverse phase high performance liquid chromatographic method has been developed for the simultaneous estimation of Valsartan and Cilnidipine. The purposed RP-HPLC method utilizes stationary phase and consists of symmetry C18 (250 × 4.6 mm, 5 μm in particle size) with a mobile phase comprising of Acetonitrile: Ammonium Acetate Buffer (75:25%v/v) pH 5.0 adjusted by Triethylamine at a flow rate of 1.0 mL/min, column temperature of 25 °C and UV detection at 240 nm. The retention time of Valsartan and Cilnidipine were 2.45 and 8.43 min respectively. The linearity was found to be in the range of 4–20 g/mL and 24–120 μg/mL for Cilnidipine and Valsartan respectively. The % recovery was found to be 100.06 ± 0.226 for Cilnidipine and 99.03 ± 0.3030 for Valsartan. The proposed method was validated as per ICH guidelines and successfully applied for the determination of drugs in tablet Keywords: Cilnidipine, Valsartan, simultaneous estimation, validation, RP-HPLCCite this Article Bhole Ritesh P, Pawara Vinayak C, Chitlange Sohan S, et al. Development and validation of HPLC method for simultaneous estimation of Cilnidipine and Valsartan in bulk and tablet dosage form. Research & Reviews: A Journal of Pharmaceutical Science. 2015; 6(2): 28–36p.
発行日
巻号
セクション
ライセンス
Declaration and Copyright Transfer Form
(to be completed by authors)
I/ We, the undersigned author(s) of the submitted manuscript, hereby declare, that the above manuscript which is submitted for publication in the STM Journals(s), is not published already in part or whole (except in the form of abstract) in any journal or magazine for private or public circulation, and, is not under consideration of publication elsewhere.
· I/We will not withdraw the manuscript after 1 week of submission as I have read the Author Guidelines and will adhere to the guidelines.
· I/We Author(s ) have niether given nor will give this manuscript elsewhere for publishing after submitting in STM Journal(s).
· I/ We have read the original version of the manuscript and am/ are responsible for the thought contents embodied in it. The work dealt in the manuscript is my/ our own, and my/ our individual contribution to this work is significant enough to qualify for authorship.
· I/We also agree to the authorship of the article in the following order:
Author’s name
1. ________________
2. ________________
3. ________________
_______________
We Author(s) tick this box and would request you to consider it as our signature as we agree to the terms of this Copyright Notice, which will apply to this submission if and when it is published by this journal. |
